Capitalizing leadership acumen
for life science innovations

ANNUAL INFLAMMASOME SUMMIT UNITES WORLD RENOWNED EXPERTS IN INFLAMMASOME-TARGETED DRUG DEVELOPMENT AND ACADEMIA TO SHARE INFORMATION AND ADDRESS KNOWLEDGE GAPS IN THIS RAPIDLY EVOLVING FIELD

ZYVERSA IS WELL POSITIONED IN THE EMERGING INFLAMMASOME SPACE WITH A HIGHLY DIFFERENTIATED INFLAMMASOME ASC INHIBITOR (IC 100), WHICH HAS POTENTIAL TO TREAT A BROAD RANGE OF INFLAMMATORY DISEASES

WESTON, Fla., Sept. 9, 2021 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited panel member at the Inflammasome Therapeutics Summit 2021. The virtual conference is being held November 16-18, 2021. 

Zyversa Logo

To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, please request a one-on-one virtual meeting.

Mr. Glover and the other panel members, Paul Ashton, President & CEO of Inflammasome Therapeutics, and Anil K. Goyal, CEO & Chairperson of IMMvention Therapeutix, will address thought-provoking topics including:

  • Key learnings from recent progress and failures
  • Drivers of inflammasome therapeutics development
  • Market opportunity and untapped clinical areas
  • Bottlenecks in inflammasome therapeutics clinical success

The panel discussion will take place:

Date: Wednesday, November 17th
Time: 9:00-9:30 am ET
Event Registration Link: Inflammasome Therapeutics Summit 2021

To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, please request a one-on-one virtual meeting.

About ZyVersa Therapeutics, Inc.

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome inhibitor with potential to treat multiple inflammatory diseases, and phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS), with potential to treat other kidney diseases. For more information, please visit www.zyversa.com.

Zyversa Logo

SOURCE ZyVersa Therapeutics, Inc.